Skip to main content

Table 4 Results of subgroup analysis of pooled hazard ratios of PFS of patients

From: Prognostic value of systemic immune-inflammation index in patients with urologic cancers: a meta-analysis

Stratified analysis No. of studies Pooled HR (95% CI) P‐value Heterogeneity
I2 (%) PQ
Cancer type
 RCC 4 1.52 (0.99, 2.31) 0.050 91 < 0.001
 PC 1 11.8 (5.6, 24.87) < 0.001 NA NA
 Unclear 2 1.6 (1.23, 2.07) < 0.001 0 0.900
Urothelial cancer 2 1.6 (1.23, 2.07) < 0.001 0 0.900
Non urothelial cancer 5 2.31 (1.23, 3.69) 0.007 95 < 0.001
Treatment
 Surgery 2 1.16 (0.8, 1.7) 0.430 62 0.110
 Non surgery 4 2.65 (1.53, 4.58) < 0.001 88 < 0.001
 Mix 1 1.43 (0.89, 2.3) 0.140 NA NA
Study type
 Prospective 1 1.43 (0.89, 2.3) 0.140 NA NA
 Retrospective 6 2.03 (1.29, 3.2) 0.002 94 < 0.001
Analysis
 Multivariate 5 1.93 (1.14, 3.29) 0.010 93 < 0.001
 Univariate 2 1.91 (1.53, 2.38) < 0.001 0 0.550
  1. CI: confidence interval; HR: hazard ratio; OS: overall survival; SII: systemic immune‐inflammation index